Neurotech International Limited announced that it has successfully completed preclinical studies assessing the effects of NTI164, its proprietary medical cannabis strain, against Cytokines in Multiple Sclerosis (MS) models. The studies were performed in collaboration with RMIT University and Monash University. Results have confirmed the potent anti-inflammatory and neuro-regulatory activity of the NTI164, specifically: NTI164 reduced the inflammatory cytokine IL-12 by 44%, substantially outperforming CBD alone (15% reduction) and CBD/THC in combination (19% reduction); NTI164 reduced the inflammatory cytokine TNF-alpha by 42%, outperforming CBD alone (29% reduction) and CBD/THC in combination (25% reduction). The preclinical studies demonstrated that NTI164 strain can suppress the expression of key MS markers, IL-12 and TNF-alpha, in human derived microglial cells. These studies are an expansion of the earlier findings in which NTI164 significantly suppressed the expression of COX-2 inhibition in human derived microglial cells. Cytokines play an important role in the neuroinflammatory responses. IL-12 and TNF-alpha are both elevated in MS patients and are thought to play a major role in the pathology. The xompany has assessed similar formulations in these preclinical models, 1:1 CBD/THC mixtures. Results have shown that NTI164 is significantly more effective in suppressing key biomarkers versus CBD/THC formulation. Recent patent filings by NTI will also allow the company to assess combination formulation options with NTI164 and proven MS therapies to improve treatment efficacy and reduce side effects. This preclinical data further supports the potent anti-inflammatory properties of NTI164 and broadens the potential applications to now include MS in addition to Autism Spectrum Disorder (ASD).